Medication info
Oscovan Film-Coated Tablets 80 mg (Valsartan)

Oscovan Film-Coated Tablets 80 mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›80mg / 1 tablet
Manufacturer / importer
Oscorea Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201602896 · Approved 2016.05.24

Summary

Main use
Treatment of essential hypertension; reduction of the risk of death after myocardial infarction; treatment of heart failure
Who takes it
Adults · Children
Adult dose
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this medicine at the same time every day (e.g., in the morning). 1) Adults: Regardless of sex or race, oral administration of valsartan 80 mg once daily is recommended. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be co-administered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients undergoing dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with reduced intravascular volume (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily and do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily; it may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, reduction of the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily; over the following weeks, the dose is increased according to the patient's tolerability to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with ACE inhibitors is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or patients undergoing dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, it is preferable not to exceed a daily dose of 80 mg. If administering more than 80 mg daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Oscorea Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension; reduction of the risk of death after myocardial infarction; treatment of heart failure

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
View approved original text

This medication is effective in controlling blood pressure in patients with essential hypertension and can be safely used in patients with heart failure who are intolerant to ACE inhibitors. Additionally, it helps to reduce the risk of death in clinically stable patients with impaired left ventricular function after myocardial infarction. In short, it is used for managing hypertension, treating heart failure, and reducing the risk of death after myocardial infarction.

How to take

Adult dose

1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this medicine at the same time every day (e.g., in the morning). 1) Adults: Regardless of sex or race, oral administration of valsartan 80 mg once daily is recommended. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be co-administered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients undergoing dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with reduced intravascular volume (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily and do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily; it may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, reduction of the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily; over the following weeks, the dose is increased according to the patient's tolerability to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with ACE inhibitors is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or patients undergoing dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, it is preferable not to exceed a daily dose of 80 mg. If administering more than 80 mg daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus when taken during pregnancy, especially in the second and third trimesters; it should be discontinued immediately upon confirmation of pregnancy. Women who are pregnant or may become pregnant, nursing mothers, patients with certain liver or kidney conditions, and patients with hereditary angioedema should not take this medication. Elderly patients, those with hyperkalemia, liver dysfunction, or heart failure should use this medication with caution and monitor blood pressure and kidney function frequently. Blood pressure may drop dramatically when starting this medication, so patients undergoing dialysis or taking diuretics, or those on strict salt restriction should start with a low dose and monitor their condition carefully. During treatment, side effects such as headaches, dizziness, fatigue, cough, and diarrhea may occur, and in rare cases, serious adverse reactions like angioedema, kidney damage, hepatitis, or hypoglycemia may occur. Particular caution is needed as there is an increased risk of elevated serum potassium levels in patients with hyperkalemia or those taking potassium-sparing diuretics. Interactions may occur with other antihypertensives, non-steroidal anti-inflammatory drugs (NSAIDs), and lithium formulations, so consultation with a physician is necessary. Pregnant women should be cautioned against using this medication, and nursing mothers should either avoid it or discontinue breastfeeding. Safety and efficacy in children and adolescents have not been established, so use is not recommended. In case of overdose, severe hypotension or shock may occur, and immediate hospital treatment should be sought if suspected. This medication should be stored out of reach of children, and care should be taken not to transfer it to other containers.

Side effects

  • Headache
  • dizziness
  • viral infection
  • upper respiratory tract infection
  • cough
  • diarrhea
  • fatigue
  • rhinitis
  • sinusitis
  • abdominal pain
Show 44 more
  • colicky pain
  • nausea
  • pharyngitis
  • arthralgia
  • hypotension
  • orthostatic dizziness
  • orthostatic hypotension
  • renal dysfunction
  • hyperkalemia
  • angioedema
  • edema
  • erythema
  • pruritus
  • serum sickness
  • vasculitis
  • syncope
  • epistaxis
  • hepatitis
  • arrhythmia
  • intestinal vascular edema
  • interstitial pneumonia
  • hypoglycemia
  • shock
  • loss of consciousness
  • rhabdomyolysis
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • bullous dermatitis
  • decreased hematocrit
  • decreased hemoglobin
  • neutropenia
  • increased BUN
  • rigidity
  • weakness
  • dyspepsia
  • anemia
  • tinnitus
  • nervous tension
  • decreased motor function
  • confusion
  • chest pain
  • rash
  • myalgia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. To maintain its effectiveness, it should be kept in a cool place below 30 degrees Celsius.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.